June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Diagnostic efficacy of 24-2C SITA Standard global summary indices
Author Affiliations & Notes
  • Amanda Carpenter
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Thomas Callan
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Sophia Yu
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Nolleisha Graves
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Charles Wu
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Iryna A. Falkenstein
    Glaucoma Specialists of San Francisco, Oakland, California, United States
  • Todd Severin
    East Bay Eye Center, San Ramon, California, United States
  • Gary C Lee
    Carl Zeiss Meditec, Inc., Dublin, California, United States
  • Footnotes
    Commercial Relationships   Amanda Carpenter Carl Zeiss Meditec, Inc., Code E (Employment); Thomas Callan Carl Zeiss Meditec, Inc., Code E (Employment); Sophia Yu Carl Zeiss Meditec, Inc., Code E (Employment); Nolleisha Graves Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor); Charles Wu Carl Zeiss Meditec, Inc., Code C (Consultant/Contractor); Iryna Falkenstein Glaucoma Specialists of San Francisco, Code C (Consultant/Contractor); Todd Severin East Bay Eye Center, Code C (Consultant/Contractor); Gary Lee Carl Zeiss Meditec, Inc., Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1264 – A0404. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amanda Carpenter, Thomas Callan, Sophia Yu, Nolleisha Graves, Charles Wu, Iryna A. Falkenstein, Todd Severin, Gary C Lee; Diagnostic efficacy of 24-2C SITA Standard global summary indices. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1264 – A0404.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : 24-2C SITA Standard is a prototype visual field (VF) test using the 24-2C test pattern, which added 10 new test locations to the 24-2. In this clinical study, we explored the diagnostic efficacy of global summary indices derived from 24-2C SITA Standard in a preliminary cohort of normal and glaucomatous eyes.

Methods : 24-2C SITA Standard (SS-C) and 24-2C SITA Faster (SFR-C) VFs were acquired on an HFA3 perimeter (ZEISS, Dublin, CA) at each of two visits on one eye of a group of 32 normal and 34 glaucomatous subjects. 24-2 SITA Standard (SS) and 24-2 SITA Faster (SFR) VFs were extracted from 24-2C VFs. The last qualified test for each VF was used for data analyses. The diagnostic performance for the VF global indices of Mean Deviation (MD), Visual Field Index (VFI) and Pattern Standard Deviation (PSD) was assessed using the area under the receiver operator characteristic curve (AROC) and sensitivity. AROCs were compared to those of SS and SS-C.

Results : Mean age was 58.1 (standard deviation, SD: 7.6; range: 44 to 75) years for normal subjects and 71.6 (SD: 9.2; range 53 to 98) years for glaucoma patients. Mean MDSS-C was 0.35 (SD: 1.02; range: -1.63 to 2.45) dB and -8.57 (SD: 8.15; range: -25.29 to 1.39) dB in normal and glaucomatous eyes (P<0.001), respectively (see Table 1). The AROC of MDSS-C was 0.95. Compared to MDSS-C, the AROCs for MDSS, MDSFR, and MDSFR-C were 0.94 (P=0.120), 0.94 (P=0.563), and 0.95 (P=0.889), as shown in Table 2. The sensitivities at 95% specificity were 82.0% (MDSS), 71.0% (MDSFR), 85.0% (MDSS-C), and 76.0% (MDSFR-C), respectively. The AROC of VFISS-C was 0.97. Compared to VFISS-C, the AROCs for VFISS, VFISFR, and VFISFR-C were 0.96 (P=0.799), 0.96 (P=0.881), and 0.96 (P=0.873), as shown in Table 2. The sensitivities at 95% specificity were 88.0% (VFISS), 88.0% (VFISFR), 88.0% (VFISS-C), and 85.0% (VFISFR-C), respectively. Similar results were observed for PSD.

Conclusions : The findings in this preliminary cohort suggest that the new 24-2C SITA Standard global summary indices may have similar (non-inferior) diagnostic performance to those of the existing 24-2 and 24-2C SITA strategies. In terms of global summary indices, 24-2C SITA Standard may provide a reasonable clinical alternative to current clinical threshold strategies for the diagnosis of glaucoma.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Table 1. Summary Indices (Mean ± SD)

Table 1. Summary Indices (Mean ± SD)

 

Table 2. AROC with 95% Confidence Interval and Sensitivity at 95% Specificity

Table 2. AROC with 95% Confidence Interval and Sensitivity at 95% Specificity

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×